echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sichuan Creed, the only short-acting muscle relaxant in China, won the first imitation!

    Sichuan Creed, the only short-acting muscle relaxant in China, won the first imitation!

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to the latest data from Meinnet.
    com, the sales volume of terminal muscle relaxants in China's public medical institutions in 2021H1 increased by 32.
    47% year-on-year, and the total market share of TOP10 products exceeded 95%.
    Ammonium has met the requirements for centralized procurement, and the muscle relaxant market will be shuffled; although micuronium has not been squeezed into the TOP10, its sales growth rate in 2021H1 leads all muscle relaxants, reaching 185.
    71%, and is ranked in muscle relaxant products With the improvement year by year, Sichuan Creed successfully won the first imitation in April 2021

    .

    Muscle relaxant "Yi Ge" is included in centralized procurement, and the market for over 4 billion is shuffled

    Muscle relaxant "Yi Ge" is included in centralized procurement, and the market for over 4 billion is shuffled

    Muscle relaxants (hereinafter referred to as muscle relaxants) can selectively act on neuromuscular junctions, temporarily interfering with normal neuromuscular excitement transmission, and causing muscle relaxation
    .
    Muscle relaxants are mainly used for tracheal intubation during induction of surgical anesthesia or to maintain muscle relaxation during general anesthesia.
    It can also be used to eliminate the antagonism of spontaneous breathing to the ventilator during mechanical ventilation in critically ill patients, and to treat tetanus, status epilepticus and other muscles Spastic disease

    .

    Muscle relaxants are mainly used in general anesthesia.
    The commonly used muscle relaxants in anesthesiology are mainly divided into two categories, one is depolarizing muscle relaxants/non-competitive muscle relaxants, and the other is atracurium /Cisatracurium (medium-acting), rocuronium (medium-acting), micuronium (short-acting) and other non-depolarizing muscle relaxants/competitive muscle relaxants

    .
    In clinical practice, medium and short-acting non-depolarizing muscle relaxants are used more frequently

    .

    With the continuous increase in the number of hospitalizations and operating units in China's medical institutions, the muscle relaxant market is expanding year by year
    .
    According to data from Meinenet, in 2020, the sales volume of terminal muscle relaxants in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 4 billion yuan

    .
    With the normalization of the epidemic, the number of doctors and operating units in hospitals has gradually recovered, and the muscle relaxant market has recovered.
    The sales scale of 2021H1 exceeded 2 billion yuan, an increase of 32.
    47% over the same period last year

    .

    Figure 1: Sales of terminal muscle relaxants in public medical institutions in China (unit: ten thousand yuan)

    Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern

    The market concentration of muscle relaxants in China's public medical institutions is relatively high.
    The total market share of TOP10 products in the first half of 2021 exceeds 95%.
    Although micuronium chloride has not squeezed into the TOP10, its growth rate in 2021H1 is that of all muscle relaxants.
    The highest among them, reaching 185.
    71%, and the ranking of muscle relaxant products has been increasing year by year, from the 16th in 2018 to the 13th in 2021H1, the market potential is great

    .

    Subdivided into anesthesiology muscle relaxants, non-depolarizing muscle relaxants are the most clinically used category.
    Cisatracurium benzenesulfonate has a market share of over 70%, and rocuronium has a market share of 23%.
    Immediately afterwards

    .

    Table 1: Sales of commonly used muscle relaxants in terminal anesthesia departments of public medical institutions in China in 2021H1

    Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern

    At present, Cisatracurium Benzene Sulfonium Injection (including Cisatracurium Benzene Sulfonium Injection and Cisatracurium Benzene Sulfonium Injection) has been included in the fifth batch of national centralized procurement, and the number of companies that have been evaluated for Rocuronium Bromide Injection There are already 4 companies, with a high probability of being selected for the seventh batch of centralized procurement
    .
    With the normalization of centralized procurement, the muscle relaxant market will continue to reshuffle, and the sales of stock products will be affected to a certain extent due to the sharp decline in prices.
    Newly approved products are expected to quickly seize the market through winning bids

    .

    Table 2: Muscle relaxants that have been included in the national collection

    Source: Shanghai Sunshine Pharmaceutical Purchasing Network

    The only short-acting muscle relaxant, Sichuan Creed won the first imitation

    The only short-acting muscle relaxant, Sichuan Creed won the first imitation

    According to data from Minaiwang, there are currently six muscle relaxant companies that have passed or deemed to have passed the consistency evaluation, including Sichuan Creed Pharmaceutical’s Micuronium Chloride Injection, and Livzon Group’s Livzon Pharmaceutical Factory’s Dantrolene Sodium for Injection.
    , Wuhan Hengxinyuan Pharmaceutical's Dantrolene Sodium Capsule was the first imitation (including the first imitation of the dosage form) and was approved and deemed to have been reviewed

    .

    Table 3: Partial over-assessment of muscle relaxants (including new classifications for production)

    Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database

    Micuronium chloride is highly selective and the only non-depolarizing neuromuscular blocker that does not require anticholinesterase antagonism.
    It is also the only short-acting muscle relaxant in China with rapid onset, It has the advantages of reliable function, rapid recovery, no adverse cardiovascular reactions, no accumulation, etc.
    It is especially suitable for special populations such as children and the elderly

    .
    Micuronium satisfies the characteristics of an ideal muscle relaxant, and is more in line with the current rapid clinical development of accelerated rehabilitation surgery (ERAS) concept

    .

    Sichuan Creed Pharmaceutical's Micuronium Chloride Injection was approved for production in April 2021, and it is the first domestic imitation.
    Many quality inspection indicators are in line with national regulations, and there is no difference compared with the original product

    .
    In addition, its registration standards have been upgraded twice compared with the original products, with stronger impurity detection capabilities, lower impurity content, and better quality control

    .

    In terms of muscle relaxants, Sichuan Creed Pharmaceuticals has created anesthesia line products with different effects and durations.
    In addition to the above-mentioned micuronium injection, the company also has a long-acting muscle relaxant-pipecuronium for injection.
    At present, only Hungarian Jirui and Sichuan Creed Pharmaceuticals have the approval for the production of this product in China

    .

    Note: The original text has been deleted

    Source: Minet database

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.